EHA Library - The official digital education library of European Hematology Association (EHA)

HEMOSTATIC CHARACTERIZATION OF POST-COVID-19 CONVALESCENT PLASMA DONORS: THE BERGAMO EXPERIENCE
Author(s): ,
Carmen Julia Tartari
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Giulia Milani
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Francesco Salvetti
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Marina Marchetti
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Laura Russo
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Alfonso Vignoli
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Massimiliano Vitali
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Luca Barcella
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Maurizio Cefis
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Patricia Gomez-Rosas
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Francesca Schieppati
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Giulia Ravasio
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Laura Castellani
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Gianmariano Marchesi
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Eleonora Sanga
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
,
Debora Romeo
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy
Anna Falanga
Affiliations:
Immunohematology and Transfusion Medicine,Papa Giovanni XXIII Hospital,Bergamo,Italy;School of Medicine and Surgery,University of Milano Bicocca,Milan,Italy
EHA Library. Tartari C. 06/09/21; 324700; S292
Dr. Carmen Tartari
Dr. Carmen Tartari
Contributions
Abstract
Presentation during EHA2021: All Oral presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: S292

Type: Oral Presentation

Session title: Transfusion medicine

Background

Severe COVID-19 is associated with a profound derangement of the hemostatic system characterized by hypercoagulability, complement activation and endothelial cell perturbation. After disease resolution, some convalescent subjects still experience post-COVID-19 symptoms. No information is available on persistence of hemostatic alterations in this setting. Bergamo city, represents one of the first and most affected area by SARS-CoV-2 infection in the world. For this reason, since the beginning we were actively involved in hyperimmune plasma collection from COVID-19 convalescent subjects. 

Aims

In this study, in a large cohort of convalescent donors of hyperimmune plasma, we aimed to characterize select hemostatic parameters of hypercoagulability and endothelial cell perturbation and their association with disease severity, demographic characteristics, and antibody levels.

Methods
Recovered COVID-19 patients eligible to plasma donation were tested for the SARS-CoV-2 antibodies by the anti-N IgG SARS-CoV-2 antibodies (Abbott Laboratories, IL, USA, Anti-N Abs), and/or the anti-S IgG SARS-CoV-2 antibodies (Liaison-Diasorin, Sallugia-VC, Italy, Anti-S Abs), according to the manufacturer’s instructions. Fibrinogen, protein C, protein S, factor V, factor VIII, factor XIII, D-dimer, and von Willebrand factor (vWF) were assessed.

Results

425 subjects have been included (275M/150F) with a median age of 48 years (range: 19-67 years). Among convalescent subjects admitted to the donation, male gender, age > 40 years, and previous hospitalization for COVID-19, were identified as independent predictive factors for significantly (p<0.001) higher levels of SARS-CoV-2 IgG (both anti-S and anti-N). Hemostatic parameters including fibrinogen, protein S, factor V, factor VIII, factor XIII, and D-dimer were not different between severe and non-severe COVID-19. Differently, convalescent subjects with previous severe COVID-19 showed significantly higher levels of vWF (124±40 vs 121±41 %, p<0.001) and PC (119±19 vs 109±19 %, p<0.001) compared with non-severe COVID-19 subjects. In addition, significant positive correlations were found between vWF levels and anti-S Abs (vWF antigen r=0.216; vWF activity r=0.257 and vWF RiCof r=0.226, p<0.01).

Conclusion
Our data show that gender, age and severe disease can be potential predictors of an increased immunological response. Furthermore, convalescent subjects show a persistently high vWF levels, suggesting a persistence of the endothelial activation, despite of clinical disease remission.

Keyword(s): Antibody, COVID-19, Donor, Hemostasis

Presentation during EHA2021: All Oral presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: S292

Type: Oral Presentation

Session title: Transfusion medicine

Background

Severe COVID-19 is associated with a profound derangement of the hemostatic system characterized by hypercoagulability, complement activation and endothelial cell perturbation. After disease resolution, some convalescent subjects still experience post-COVID-19 symptoms. No information is available on persistence of hemostatic alterations in this setting. Bergamo city, represents one of the first and most affected area by SARS-CoV-2 infection in the world. For this reason, since the beginning we were actively involved in hyperimmune plasma collection from COVID-19 convalescent subjects. 

Aims

In this study, in a large cohort of convalescent donors of hyperimmune plasma, we aimed to characterize select hemostatic parameters of hypercoagulability and endothelial cell perturbation and their association with disease severity, demographic characteristics, and antibody levels.

Methods
Recovered COVID-19 patients eligible to plasma donation were tested for the SARS-CoV-2 antibodies by the anti-N IgG SARS-CoV-2 antibodies (Abbott Laboratories, IL, USA, Anti-N Abs), and/or the anti-S IgG SARS-CoV-2 antibodies (Liaison-Diasorin, Sallugia-VC, Italy, Anti-S Abs), according to the manufacturer’s instructions. Fibrinogen, protein C, protein S, factor V, factor VIII, factor XIII, D-dimer, and von Willebrand factor (vWF) were assessed.

Results

425 subjects have been included (275M/150F) with a median age of 48 years (range: 19-67 years). Among convalescent subjects admitted to the donation, male gender, age > 40 years, and previous hospitalization for COVID-19, were identified as independent predictive factors for significantly (p<0.001) higher levels of SARS-CoV-2 IgG (both anti-S and anti-N). Hemostatic parameters including fibrinogen, protein S, factor V, factor VIII, factor XIII, and D-dimer were not different between severe and non-severe COVID-19. Differently, convalescent subjects with previous severe COVID-19 showed significantly higher levels of vWF (124±40 vs 121±41 %, p<0.001) and PC (119±19 vs 109±19 %, p<0.001) compared with non-severe COVID-19 subjects. In addition, significant positive correlations were found between vWF levels and anti-S Abs (vWF antigen r=0.216; vWF activity r=0.257 and vWF RiCof r=0.226, p<0.01).

Conclusion
Our data show that gender, age and severe disease can be potential predictors of an increased immunological response. Furthermore, convalescent subjects show a persistently high vWF levels, suggesting a persistence of the endothelial activation, despite of clinical disease remission.

Keyword(s): Antibody, COVID-19, Donor, Hemostasis

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies